You are here

Home » Content

Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu

A Case with Thrombocytopenia Developing after Tirofiban Treatment

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Platelets have a central role in many cardiovascular events. Tirofiban is a glycoprotein (GP) IIb/IIIa receptor inhibitor that prevents platelet aggregation. In this report, it was aimed to review the thrombocytopenia induced by tirofiban treatment and other causes of thrombocytopenia.
Bookmark/Search this post with
Abstract (Original Language): 
Trombositler birçok kardiyovasküler olayda merkezi role sahiptirler. Tirofiban, trombosit agregasyonunu önleyen bir glikoprotein (GP) IIb/IIIa reseptör inhibitörüdür. Bu olguda tirofiban tedavisi sonrası gelişen trombositopeni ve trombositopeni yapan diğer nedenlerin gözden geçirilmesi amaçlandı.
FULL TEXT (PDF): 
PDF icon arastirmax-tirofiban-tedavisi-sonrasi-gelisen-trombositopeni-olgusu.pdf
  • 1
55-57
  • Turkish

REFERENCES

References: 

1. Boersma E, Harrington EA, Moliterno DJ, White H, Simoons
ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary
syndromes: a metaanalysis of all major randomised clinical trials.
Lancet 2002;359(9302):189-98.
2. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous
glycoprotein IIb/IIIa receptor antagonists reduce mortality after
percutaneous coronary interventions. J Am Coll Cardiol
2003;41:26-32.
3. Özmen F, Atalar E, Özer N. Akut koroner sendromda
trombositler ve glikoprotein IIb/IIIa inhibitörleri. Türk J Cardiol
2007;10:91-100.
4. Abrams CS, Cines DB. Thrombocytopenia after treatment with
platelet glycoprotein IIb/IIIa inhibitors. Curr Hematol Rep
2004;3:143-47.
5. Aster RH. Drug-induced immune thrombocytopenia: an
overview of pathogenesis. Semin Hematol 1999;362-66.
6. Holmes MB, Kabbani S, Watkins M, Battle RW, Schneider DJ.
Abciximab associated pseudothrombocytopenia. Circulation
2000;101:938–39.
7. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial
intereactions: sepsis, HIT and antiphospholipid syndrome.
Hematology 2003;497-519.
8. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M,
Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia
after treatment with tirofiban or eptifibatide Thrombocytopenia
after tirofiban is associated with antibodies specific for ligandoccupied
GPIIb/IIIa. Blood 2002;100:2071-6.
9. Curtis B, Swyers J, Divgi A, McFarland J, Aster R.
Thrombocytopenia after second exposure to abciximab is caused
by antibodies that recognize abciximab coated platelets. Blood
2002;99:2054-9.
Tirofiban Tedavisi Sonrası Gelişen Trombositopeni Olgusu
57
10. Eryonucu B, Tuncer M, Erkoc R. Repetitive profound
thrombocytopenia after treatment with tirofiban: a case report.
Cardiovasc Drugs Therapy 2004;18:503-5.
11. Demirkan B, Guray Y, Guray U, Korkmaz S. Differential
diagnosis and management of acute profound thrombocytopenia
by tirofiban: a case report. J Thromb Thrombolysis 2006;22:77-8.
12. Beiras-Fernandez A, Kowert A, Jiru P, Weis M, Spannagl M,
Reichart B, Schmoeckel M. Acute profound thrombocytopenia
after treatment with tirofiban and off-pump coronary artery
bypass grafting. Ann Thorac Surg 2009;87(2):629-31.

Thank you for copying data from http://www.arastirmax.com